Search Results - "Aaltonen, Kalle"

Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis by Aaltonen, Kalle J, Virkki, Liisa M, Malmivaara, Antti, Konttinen, Yrjö T, Nordström, Dan C, Blom, Marja

“…Five-tumour necrosis factor (TNF)-blockers (infliximab, etanercept, adalimumab, certolizumab pegol and golimumab) are available for treatment of rheumatoid…”
Get full text

The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review by Joensuu, Jaana T, Huoponen, Saara, Aaltonen, Kalle J, Konttinen, Yrjö T, Nordström, Dan, Blom, Marja

“…Economic evaluations provide information to aid the optimal utilization of limited healthcare resources. Costs of biologics for Rheumatoid arthritis (RA) are…”
Get full text

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis by Huoponen, Saara, Aaltonen, Kalle J, Viikinkoski, Jaana, Rutanen, Jarno, Relas, Heikki, Taimen, Kirsi, Puolakka, Kari, Nordström, Dan, Blom, Marja

“…The objective of this study was to evaluate the cost-effectiveness of abatacept, tocilizumab, and tumor necrosis factor (TNF) inhibitors as compared with…”
Get full text

Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice by Aaltonen, Kalle J, Ylikylä, Suvi, Tuulikki Joensuu, Jaana, Isomäki, Pia, Pirilä, Laura, Kauppi, Markku, Rannio, Tuomas, Eklund, Kari, Blom, Marja, Nordström, Dan

“…Efficacy of TNF inhibitors in the treatment of RA assessed in randomized controlled trials (RCTs) may not be fully comparable to routine care owing to the…”
Get full text

Effectiveness and drug survival of tnf-inhibitors in the treatment of psoriatic arthritis: A prospective cohort study by Kalle, Aaltonen, Arto, Heinonen, Jaana, Joensuu, Pinja, Parmanne, Anna, Karjalainen, Tuire, Varjolahti-Lehtinen, Toini, Uutela, Maija, Puurtinen-Vilkki, Leena, Arstila, Marja, Blom, Tuulikki, Sokka, Dan, Nordström

“…Abstract Background and Objectives Tumor Necrosis Factor (TNF)-inhibitors are used to treat psoriatic arthritis (PsA), but only a limited number of…”
Get full text

Effectiveness and Drug Survival of TNF Inhibitors in the Treatment of Ankylosing Spondylitis: A Prospective Cohort Study by Heinonen, Arto V, Aaltonen, Kalle J, Joensuu, Jaana T, Lähteenmäki, Jukka P, Pertovaara, Marja I, Romu, Matti K, Hirvonen, Hanna E, Similä, Aki K, Blom, Marja L, Nordström, Dan C

“…The aim of this research was to describe the effectiveness and drug survival of tumor necrosis factor (TNF) inhibitors in the treatment of ankylosing…”
Get full text

Cost-effectiveness of biologic compared with conventional synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a Register study by Joensuu, Jaana T, Aaltonen, Kalle J, Aronen, Pasi, Sokka, Tuulikki, Puolakka, Kari, Tuompo, Riitta, Korpela, Markku, Vasala, Mikko, Ilva, Kirsti, Nordström, Dan, Blom, Marja

“…The aim of this study was to explore the cost-effectiveness of biological DMARDs (bDMARDs) compared with conventional synthetic DMARDs (csDMARDs) for RA using…”
Get full text

Do biologic drugs affect the need for and outcome of joint replacements in patients with rheumatoid arthritis? A register-based study by Aaltonen, Kalle J., MSc (pharm), PhD, Virkki, Liisa M., MSc (pharm), PhD, Jämsen, Esa, MD, PhD, Sokka, Tuulikki, MD, PhD, Konttinen, Yrjö T., MD, PhD, Peltomaa, Ritva, MD, PhD, Tuompo, Riitta, MD, Yli-Kerttula, Timo, MD, PhD, Kortelainen, Saara, MD, Ahokas-Tuohinto, Pirkko, MD, Blom, Marja, PhD, Nordström, Dan C., MD, PhD

“…Abstract Objectives The aim was to study the incidence of joint replacements among biologic drug and disease-modifying anti-rheumatic drug (DMARD) users as…”
Get full text

A survey on the medication adherence to methotrexate among rheumatoid arthritis patients treated with self-administered biologic drugs by Aaltonen, Kalle J, Turunen, Juha H, Sokka, Tuulikki, Puolakka, Kari, Valleala, Heikki

“…Methotrexate (MTX) is the most widely used co-therapy among rheumatoid arthritis (RA) patients using biological disease-modifying anti-rheumatic drugs…”
Get full text

Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study by Cordtz, Rene Lindholm, Askling, Johan, Delcoigne, Benedicte, Smedby, Karin E, Baecklund, Eva, Ballegaard, Christine, Isomäki, Pia, Aaltonen, Kalle, Gudbjornsson, Bjorn, Love, Thorvardur Jon, Provan, Sella Aarrestad, Michelsen, Brigitte, Sexton, Joseph, Dreyer, Lene, Hellgren, Karin

“…To evaluate the risk of haematological malignancies in patients with psoriatic arthritis (PsA) overall, and in relation to treatment with tumour necrosis…”
Get full text

Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers by Delcoigne, Benedicte, Kopp, Tine Iskov, Arkema, Elizabeth V, Hellgren, Karin, Provan, Sella Aarrestad, Relas, Heikki, Aaltonen, Kalle, Trokovic, Nina, Gudbjornsson, Bjorn, Grondal, Gerdur, Klami Kristianslund, Eirik, Lindhardsen, Jesper, Dreyer, Lene, Askling, Johan

“…ObjectiveTo compare incidences of neuroinflammatory events, including demyelinating disease (DML), inflammatory polyneuropathies (IPN) and multiple sclerosis…”
Get full text

How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers by Chatzidionysiou, Katerina, Delcoigne, Bénédicte, Frisell, Thomas, Hetland, Merete L, Glintborg, Bente, dreyer, lene, Cordtz, René, Zobbe, Kristian, Nordström, Dan, Trokovic, Nina, Aaltonen, Kalle, Provan, Sella Aarrestad, Grondal, Gerdur, Gudbjornsson, Bjorn, Askling, Johan

“…Correspondence to Katerina Chatzidionysiou; aikaterini.chatzidionysiou@ki.se Immune competence is of importance for the occurrence and outcome of malignancies,…”
Get full text

Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy by Aaltonen, Kalle Jyri, Joensuu, Jaana Tuulikki, Virkki, Liisa, Sokka, Tuulikki, Aronen, Pasi, Relas, Heikki, Valleala, Heikki, Rantalaiho, Vappu, Pirilä, Laura, Puolakka, Kari, Uusitalo, Tea, Blom, Marja, Konttinen, Yrjö Tapio, Nordström, Dan

“…Because of the role of tumor necrosis factor (TNF) in host defense, it was hypothesized that its inhibition might lead to an increased risk of malignancies and…”
Get full text

Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Initiating Biologics and Controls: Data From 5 Nordic Registries by Provan, Sella Aarrestad, Ljung, Lotta, Kristianslund, Eirik Klami, Michelsen, Brigitte, Uhlig, Till, Jonmundsson, Thorarinn, Sexton, Joe, Gudbjornsson, Bjorn, Di Giuseppe, Daniela, Hetland, Merete Lund, Reynisdottir, Gudrun Bjork, Glintborg, Bente, Relas, Heikki, Aaltonen, Kalle, Kvien, Tore Kristian, Askling, Johan

“…Objective Interstitial lung disease (ILD) is one of the most common pulmonary manifestations of rheumatoid arthritis (RA), but its prevalence has not been…”
Get full text

Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study by Hellgren, Karin, Ballegaard, Christine, Delcoigne, Bénédicte, Cordtz, René, Nordström, Dan, Aaltonen, Kalle, Gudbjornsson, Bjorn, Love, Thorvardur Jon, Aarrestad Provan, Sella, Sexton, Joe, Zobbe, Kristian, Kristensen, Lars Erik, Askling, Johan, Dreyer, Lene

“…To investigate whether TNF inhibitors (TNFi) are associated with increased risk of solid cancer in patients with psoriatic arthritis (PsA). From the Nordic…”
Get full text

One‐Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses by Glintborg, Bente, Lindström, Ulf, Giuseppe, Daniela Di, Provan, Sella Aarrestad, Gudbjornsson, Bjorn, Hetland, Merete Lund, Michelsen, Brigitte, Wallman, Johan K., Aaltonen, Kalle, Hokkanen, Anna‐Mari, Nordström, Dan, Jørgensen, Tanja Schjødt, Hansen, Rebekka Lund, Geirsson, Arni Jon, Grøn, Kathrine Lederballe, Krogh, Niels Steen, Askling, Johan, Kristensen, Lars Erik, Jacobsson, Lennart T. H.

“…Objective To describe baseline characteristics and to compare treatment effectiveness of secukinumab versus tumor necrosis factor inhibitors (TNFi) in patients…”
Get full text

The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries by Di Giuseppe, Daniela, Lindström, Ulf, Aaltonen, Kalle, Relas, Heikki, Provan, Sella, Gudbjornsson, Bjorn, Hetland, Merete Lund, Askling, Johan, Kauppi, Markku, Geirsson, Arni Jon, Chatzidionysiou, Katerina, Jørgensen, Tanja Schjødt, Dreyer, Lene, Michelsen, Brigitte, Jacobsson, Lennart, Glintborg, Bente

“…In axial spondyloarthritis (axSpA), switching between multiple biologic or targeted synthetic (b/ts-) DMARDs might indicate difficult-to-treat disease. We…”
Get full text

Interstitial lung disease in rheumatoid or psoriatic arthritis patients initiating biologics, and controls - data from five Nordic registries by Provan, Sella Aarrestad, Ljung, Lotta, Kristianslund, Eirik Klami, Michelsen, Brigitte, Uhlig, Till, Jonmundsson, Thorarinn, Sexton, Joe, Gudbjornsson, Bjorn, Di Giuseppe, Daniela, Hetland, Merete Lund, Reynisdottir, Gudrun Bjork, Glintborg, Bente, Relas, Heikki, Aaltonen, Kalle, Kvien, Tore Kristian, Askling, Johan

“…Interstitial lung disease (ILD) is one of the most common pulmonary manifestation of rheumatoid arthritis (RA), but its prevalence has not been investigated in…”
Get full text

Impact of TNF inhibitor medication on working ability in axial spondyloarthritis: an observational national registry-based cohort study by Hokkanen, Anna-Mari, Aaltonen, Kalle, Relas, Heikki, Rutanen, Jarno, Kononoff, Aulikki, Taimen, Kirsi, Kauppi, Markku, Puolakka, Kari, Trokovic, Nina, Nordström, Dan

“…Abstract Objective The aim was to investigate the effect of TNF inhibitor (TNFi) initiation on working ability and health-care resource utilization among…”
Get full text

Effectiveness of a second biologic after failure of a non-tumor necrosis factor inhibitor as first biologic in rheumatoid arthritis by Chatzidionysiou, Katerina, Hetland, Merete Lund, Frisell, Thomas, Di Giuseppe, Daniela, Hellgren, Karin, Glintborg, Bente, Nordström, Dan, Peltomaa, Ritva, Aaltonen, Kalle, Trokovic, Nina, Kristianslund, Eirik K, Kvien, Tore K, Provan, Sella A, Gudbjornsson, Bjorn, Grondal, Gerdur, Dreyer, Lene, Kristensen, Lars Erik, Jørgensen, Tanja Schjødt, Jacobsson, Lennart T H, Askling, Johan

“…In Rheumatoid Arthritis (RA), evidence regarding the effectiveness of a second biologic Disease Modifying Anti-Rheumatic Drugs (bDMARDs) in patients whose…”
Get full text